Market Place
Sourcing Support
Sandoz`s Biologic Zarxio (Filgrastim) Receives Suppl. Approval in US
22 Oct 2024 //
FDA
Tanvex Biologic Nypozi (filgrastim-txid) Receives Approval in the US
28 Jun 2024 //
FDA
Hospira`s Biologic Nivestym (filgrastim-aafi) Receives Approval in the U.S.
16 Feb 2024 //
FDA
Sicor`s Biologic Granix (Tbo-filgrastim) Receives Approval in the U.S.
21 Nov 2023 //
FDA
Aurobindo`s subsidiary to withdraw mkt authorization for EU 2 biosimilar
25 Jun 2023 //
INDIANPHARMAPOST
Kashiv`s Biologic Releuko (Filgrastim) Receives Approval in the U.S.
28 Oct 2022 //
FDA
Kashiv Bio Bags Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)
02 Mar 2022 //
BUSINESSWIRE
Amneal Enters U.S. Biosimilars Market With Approval of RELEUKOTM
01 Mar 2022 //
BUSINESSWIRE
Tanvex drug approved for marketing in Canada
18 Oct 2021 //
TAIPEITIMES
Canadian Cancer Patients Have New Affordable Treatment Option
27 Sep 2021 //
NEWSWIRE
Antonio Migliarese Promoted to CFO of CytoDyn
20 May 2021 //
GLOBENEWSWIRE
Amgen Inc`s Neupogen (Filgrastim)Receives Supplemental Approval In US
08 Feb 2021 //
FDA
Amgen Inc`s Neupogen (Filgrastim) Receives Supplemental Approval In US
09 Jan 2021 //
FDA
Teva GmbH Tevagrastim (Filgrastim) Receives Approval in Europe
14 Oct 2020 //
EMA
Sandoz working to overcome barriers to greater biosimilars uptake in US
21 Sep 2020 //
PRESS RELEASE
Study Says that Conversion of Intermediate-Risk FN Patients to Pegfilgrastim
15 May 2020 //
BIGMOLECULEWATCH
Amgen Sues Pfizer and Hospira for Patent Infringement to Hospira’s Filgrastim
28 Apr 2020 //
BIGMOLECULEWATCH
Understanding the opportunity in Japan’s biosimilar market
23 Sep 2019 //
MCKINSEY
Sandoz`s Zarxio (Filgrastim-Sndz) Receives Supplemental Approval in US
03 Aug 2019 //
FDA
Yes, Virginia (Utah, Actually), There Is §510(k) Medical Device Preemption
13 May 2019 //
DRUGANDDEVICE
BiocurePharm, Korea Announces Closing of Private Placement
28 Feb 2019 //
PRESS RELEASE
Biocure Announces a MOU with the Government of Uzbekistan to Build a Manufacturing Plant
19 Feb 2019 //
NEWS FILE CORP
Mini-Exodus From Biosimilar Space Stirs Questions
06 Dec 2018 //
RAPS
Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters
14 Nov 2018 //
FIERCE PHARMA
Understanding the Impact of Biosimilars on a Global Scale
29 Oct 2018 //
ONCLIVE
Biosimilar Filgrastim Proves Noninferior to Reference in PBCM
28 Oct 2018 //
CENTER FOR BIOSIMILARS
Mylan and Novartis to FDA: Where are the Suffixes?
26 Sep 2018 //
RAPS
BPCIA Litigation Updates: Bevacizumab, Trastuzumab, Filgrastim
17 Aug 2018 //
BIGMOLECULEWATCH
Neupogen (Filgrastim), Neulasta® (pegfilgrastim) : Amgen Inc. v. Apotex Corp.
11 Aug 2018 //
PATENT LITIGATION
Teva Announces Updated Indication &Vial Presentation for tbo-filgrastim Injectn
06 Aug 2018 //
BUSINESSWIRE
Pfizer bags approval for Neupogen biosimilar
24 Jul 2018 //
PHARMA TIMES
FDA Approves 12th Biosimilar, 2nd for Filgrastim
23 Jul 2018 //
RAPS
NEUPOGEN® (filgrastim): Amgen Inc. v. Hospira Inc. and Pfizer Inc.
23 Jul 2018 //
PATENT LITIGATION
Amgen’s Neupogen (Filgrastim ) Receives Supplemental Approval In US
20 Jun 2018 //
FDA
Enforcement Report - Week of May 16, 2018
16 May 2018 //
FDA
Neupogen® (Filgrastim): Amgen v. Adello Biologics
08 Mar 2018 //
PATENT LITIGATION
FDA Begins Adding Suffixes to Newly Approved Biologics` Names
18 Nov 2017 //
RAPS
FDA Accepts Adello Biologic’s Biosimilar BLA for Proposed Filgrastim Biosimilar
11 Sep 2017 //
BUSINESSWIRE
FDA Guidance on Biosimilar Interchangeability Elicits Diverse Views
17 Aug 2017 //
PT COMMUNITY
What’s Harder Than Making Copycat Biotech Drugs? Selling Them
16 Aug 2017 //
BLOOMBERG
